Shield by Guardant vs Oncotype DX
Side-by-side comparison of cancer screening tests.
← Back to Cancer Screening
Test Performance
| Feature | Shield by Guardant | Oncotype DX |
|---|---|---|
| Price | $1495 | Variable |
| Cancers Detected | Colorectal only | Breast recurrence risk |
| Sensitivity | 83% for CRC (54.5-65% Stage I) | N/A |
| Specificity | 90% | N/A |
| Sample Type | Blood draw | Tumor tissue |
| FDA Status | FDA approved (CRC test only) | Guideline recommended |